A Phase I Study of HRS2300 or Combined With SHR-1316 or SHR-1701 or Trametinib or Almonertinib in Patients With Advanced Malignancies
Study Details
Study Description
Brief Summary
The study is being conducted to evaluate the safety and tolerability of HRS2300 and combined with SHR-1316 or SHR-1701 or trametinib or Almonertinib.To Determine the maximum tolerated dose (MTD) and recommended Dose (RP2D) for HRS2300 monotherapy and combination therapy.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 1 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Treatment group A
|
Drug: HRS2300
HRS2300 monotherapy
|
| Experimental: Treatment group B
|
Drug: HRS2300、 SHR-1316
HRS2300 combined with SHR-1316
|
| Experimental: Treatment group C
|
Drug: HRS2300、SHR-1701
HRS2300 combined with SHR-1701
|
| Experimental: Treatment group D
|
Drug: HRS2300、trametinib
HRS2300 combined with trametinib
|
| Experimental: Treatment group E
|
Drug: HRS2300、Almonertinib
HRS2300 combined with Almonertinib
|
Outcome Measures
Primary Outcome Measures
- Number of participants with Dose limited toxicity（DLT） [Cycle 1( 4 weeks- monotherapy；3 weeks -combination）]
- Number of participants with adverse events [up to 3 years; at least once per treatment cycle]
- Determine RP2D of HRS2300 monotherapy and combination in patients with advanced malignancy [through study completion，an average of 2 years]
Enrolled sequentially from the initial dose of the trial, each subject received only one dose of the study drug and no other dose. The first subject of each dose should complete the first administration and be observed for 7 days before the other two subjects can be enrolled. After the DLT observation period of the last subject in each dose group has ended, the next dose increment can be entered. At the end of the dose escalation phase, the dose closest to the estimated toxicity probability of the target was selected as the MTD . At the end of the dose escalation, the SMC determined the RP2D based on the previous data.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Aged 18-75 years old，Male or female;
-
Patients with pathologically confirmed advanced solid tumors who did not respond to standard treatment, did not tolerate standard treatment, or were determined by the investigator to be unsuitable for standard treatment;
-
ECOG PS score of 0-1;
-
Life expectancy of ≥3 months;
-
Able and willing to provide a written informed consent.
Exclusion Criteria:
-
Receiving chemotherapy, targeted therapy, immunotherapy, radical radiotherapy or surgical treatment for less than 4 weeks before study therapy (excluding tyrosine kinase inhibitors or other small molecule targeted drugs < 2 weeks); Four weeks prior to the start of study treatment (patients who have entered the follow-up period measured by the time of last use of the experimental drug or device) were enrolled in another clinical study;
-
Drugs that affect the activity of metabolic enzyme CYP3A have been used in the past, and the eluting period from the end time to the first administration in this study is within 5 half-lives;
-
Patients with active TB within 1 year prior to the start of drug therapy or with a history of active TB infection more than 1 year prior to the start of drug therapy without proper treatment were studied;
-
Patients with other potential factors that may affect the study results or result in the premature discontinuation as determined by the investigator.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Zhejiang Cancer Hospital | Hangzhou | Zhejiang | China | 310022 |
Sponsors and Collaborators
- Jiangsu HengRui Medicine Co., Ltd.
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- HRS2300-I-101